Pharmagreen Biotech Inc.

Equities

PHBI

US71716C1099

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 01:49:06 2024-04-26 pm EDT			5-day change	1st Jan Change
0.0007 ^USD	0.00%		-12.50%	+16.67%

Feb. 21	Pharmagreen Biotech Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	CI
Jan. 09	Pharmagreen Biotech Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	CI

Pharmagreen Biotech Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023

February 20, 2024

Pharmagreen Biotech Inc. reported earnings results for the first quarter ended December 31, 2023. For the first quarter, the company reported sales was USD 0.001236 million. Net loss was USD 0.144853 million compared to USD 0.039374 million a year ago.

Latest news about Pharmagreen Biotech Inc.

Pharmagreen Biotech Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	Feb. 20	CI
Pharmagreen Biotech Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	Jan. 08	CI
Pharmagreen Biotech Inc. cancelled the transaction announced on November 2, 2022	Nov. 01	CI
Pharmagreen Starts Sales of MaxGenomicTM Supplement on Amazon.Com and Develops Its Next Pre-Workout Formulation	23-09-05	CI
Pharmagreen Biotech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	23-08-14	CI
Pharmagreen Biotech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	23-05-19	CI
Pharmagreen Biotech Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022	23-02-14	CI
Pharmagreen Biotech, Inc. Launches Online Sales for Its MaxGenomic(TM) Supplement Product	23-02-08	CI
Pharmagreen Biotech Inc. Reports Earnings Results for the Full Year Ended September 30, 2022	23-01-17	CI
Pharmagreen Biotech Inc. Auditor Raises 'Going Concern' Doubt	23-01-16	CI
Pharmagreen Biotech Inc. announced that it expects to receive $0.05 million in funding from JanBella Group, LLC	22-11-01	CI
Pharmagreen Biotech Inc. Develops a Proprietary Nutraceutical Formulation and Prepares for Product Launch	22-09-08	CI
Pharmagreen Biotech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2022	22-08-17	CI
Pharmagreen Biotech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2022	22-05-16	CI
Pharmagreen Biotech Inc. Reports Earnings Results for the First Quarter Ended December 31, 2021	22-02-22	CI
Pharmagreen Biotech Inc. completed the acquisition of Long Valley Farms LLC.	22-01-19	CI
Pharmagreen Biotech Inc. Reports Earnings Results for the Full Year Ended September 30, 2021	21-12-29	CI
Pharmagreen Biotech Inc. Auditor Raises 'Going Concern' Doubt	21-12-28	CI
Pharmagreen Biotech Inc. Reports Earnings Results for the Third Quarter Ended June 30, 2021	21-08-18	CI
Pharmagreen Biotech Inc. entered into memorandum of understanding to acquire Long Valley Farms LLC for $2.4 million.	21-08-11	CI
Pharmagreen Biotech Inc. Reports Earnings Results for the Second Quarter Ended March 31, 2021	21-05-24	CI
Pharmagreen Biotech Inc. Signs LOI to Supply Crude CBD Oil Extracted from Certified Organically Grown Hemp Biomass	21-02-16	CI
Pharmagreen Biotech Inc. Reports Earnings Results for the Full Year Ended September 30, 2020	21-01-08	CI
Pharmagreen Biotech Inc. announced a financing transaction	20-10-13	CI
Pharmagreen Biotech Inc. Reports Earnings Results for the Third Quarter Ended June 30, 2020	20-08-19	CI

Chart Pharmagreen Biotech Inc.

Duration

Period

More charts

Company Profile

Pharmagreen Biotech, Inc. is a Canada-based company. The Company is engaged in developing its line of nutraceutical products, which is a blend of therapeutic plants and mushrooms. Utilizing the Company's expertise in plant genetics, its transgenic program uses the technology available to research and create nutraceuticals, and daily supplements with the potential to improve lives and address a wide variety of ailing conditions. Its nutraceutical product, MaxGenomic Supplement, comes in a bottle with 60 enteric capsules. The MaxGenomic Supplement is a proprietary blend that consists of nine medicinal mushrooms and six medical plants to help support the human mind and body. Its other nutraceutical products are in various development stages. Its subsidiaries include WFS Pharmagreen Inc, and 1155097 BC Ltd.

Sector

Biotechnology & Medical Research

Calendar

2024-05-20 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PHARMAGREEN BIOTECH INC.	+16.67%	465K
IQVIA HOLDINGS INC.	+1.51%	42.75B
MODERNA, INC.	+8.57%	41.34B
LONZA GROUP AG	+49.22%	41.61B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research